Updated:
ConcertAI
ConcertAI applies AI and real-world data to oncology, combining a biopharma intelligence platform with the TeraRecon imaging subsidiary.
ConcertAI
The firm operates at the intersection of real-world clinical data, advanced imaging, and artificial intelligence — a posture that serves pharmaceutical sponsors and clinical research organizations running oncology trials. While its founding year and principals remain opaque in public materials, ConcertAI's visible architecture spans a data-integration layer, machine-learning applications, and a workflow-embedded software suite. The company holds a distinct footprint in medical imaging through its TeraRecon subsidiary, which is headquartered in Durham, North Carolina, and maintains offices in Frankfurt and Tokyo. ConcertAI's deployment focuses on structuring fragmented clinical data to accelerate trial design and patient matching. Its asset-class mix leans heavily into proprietary datasets and AI models licensed to biopharma. TeraRecon adds an FDA-cleared advanced visualization and AI imaging platform to the stack — an acquisition that broadens deployment from pure data services into clinician-facing diagnostic support. The subsidiary's EU and Japan offices suggest an active ex-US commercial footprint, though specific client counts and recurring-revenue metrics remain undisclosed. Team scale and adjacent vehicles are not publicly detailed. A May 2024 review of the firm's website and career postings shows a multi-city operational structure but no disclosed headcount, philanthropic foundation, or co-investment club. The TeraRecon subsidiary operates a dedicated customer-success program branded Premier Success, indicating a recurring-relationship model, though no revenue-attach rates are published. The most recent operational signal is the firm's active recruitment for AI-partner and technical-support roles across all three office locations as of late 2025. What differentiates ConcertAI structurally is its fusion of a therapeutic-area-exclusive data library with an FDA-cleared imaging-software subsidiary. Few competitors combine longitudinal oncology data, investigator-site workflow tools, and a regulated medical-device imaging platform under one roof. The architecture resembles a roll-up of parallel verticals — data, imaging, and clinical workflow — tied to a single disease-area thesis, making the firm more a silent-utility provider to drug developers than a conventional health-tech startup.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Cambridge
Corporate office
Cambridge, MA, United States
Additional offices
Durham, NC · Frankfurt, Germany · Tokyo, Japan
Sector focus
Frequently asked questions
What is the relationship between ConcertAI and TeraRecon?
TeraRecon operates as a ConcertAI subsidiary, providing FDA-cleared advanced visualization and AI-driven imaging software. It maintains its own headquarters in Durham, North Carolina, and international offices in Frankfurt and Tokyo, functioning as the imaging-software arm of ConcertAI's broader oncology data platform.
Which therapeutic areas does ConcertAI cover, and are there notable exclusions?
Public materials commit the firm to oncology and other complex diseases. Oncology remains the most visibly developed vertical, supported by real-world data assets and investigator-site tools. No explicit sector avoidances are published, though the commercial focus stays tightly coupled to cancer-research workflows.
How does ConcertAI generate revenue?
ConcertAI licenses real-world data, AI models, and workflow software to pharmaceutical sponsors and clinical research organizations. Its TeraRecon subsidiary sells imaging-software subscriptions and associated support services, creating a dual revenue architecture from data plus regulated medical-device software.
Is ConcertAI structured as a single family office or an institutional investor?
ConcertAI presents as an operating company rather than a single-family office or fund manager. Public filings and the firm's own website provide no indication of pooled investment vehicles, fund commitments, or family-office governance — it operates as a commercial health-AI business serving external enterprise clients.
What is ConcertAI's known posture on international data compliance?
The TeraRecon subsidiary lists a Data Privacy Framework Policy on its website footer, consistent with transatlantic data-transfer requirements. ConcertAI's broader platform-specific compliance certifications are not publicly detailed; regulatory posture is inferred from the subsidiary's published policies rather than a consolidated corporate disclosure.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: